Guggenheim Capital’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-14,624
| Closed | -$1.87M | – | 1593 |
|
|
2025
Q2 | $1.87M | Buy |
14,624
+797
| +6% | +$82.8K | 0.01% | 672 |
|
|
2025
Q1 | $1.22M | Buy |
13,827
+688
| +5% | +$67.1K | 0.01% | 809 |
|
|
2024
Q4 | $1.15M | Sell |
13,139
-3,725
| -22% | -$341K | 0.01% | 852 |
|
|
2024
Q3 | $1.56M | Buy |
16,864
+4,566
| +37% | +$454K | 0.01% | 911 |
|
|
2024
Q2 | $1.33M | Sell |
12,298
-4,695
| -28% | -$470K | 0.01% | 979 |
|
|
2024
Q1 | $1.61M | Sell |
16,993
-407
| -2% | -$34.9K | 0.01% | 973 |
|
|
2023
Q4 | $1.6M | Sell |
17,400
-3,261
| -16% | -$211K | 0.01% | 938 |
|
|
2023
Q3 | $1.04M | Sell |
20,661
-759
| -4% | -$40.6K | 0.01% | 1098 |
|
|
2023
Q2 | $1.35M | Sell |
21,420
-4,457
| -17% | -$242K | 0.01% | 1025 |
|
|
2023
Q1 | $1.16M | Sell |
25,877
-12,968
| -33% | -$584K | 0.01% | 1108 |
|
|
2022
Q4 | $1.7M | Buy |
38,845
+5,975
| +18% | +$287K | 0.01% | 913 |
|
|
2022
Q3 | $2.17M | Sell |
32,870
-6,314
| -16% | -$406K | 0.02% | 802 |
|
|
2022
Q2 | $1.98M | Buy |
39,184
+622
| +2% | +$36.4K | 0.02% | 893 |
|
|
2022
Q1 | $2.46M | Sell |
38,562
-1,338
| -3% | -$96K | 0.01% | 920 |
|
|
2021
Q4 | $4.27M | Sell |
39,900
-6,398
| -14% | -$669K | 0.02% | 746 |
|
|
2021
Q3 | $4.76M | Buy |
46,298
+374
| +0.8% | +$34.8K | 0.03% | 677 |
|
|
2021
Q2 | $4.04M | Buy |
45,924
+9,281
| +25% | +$850K | 0.02% | 764 |
|
|
2021
Q1 | $3.56M | Buy |
36,643
+5,906
| +19% | +$590K | 0.02% | 769 |
|
|
2020
Q4 | $3.45M | Buy |
30,737
+20,959
| +214% | +$2.21M | 0.02% | 741 |
|
|
2020
Q3 | $906K | Buy |
9,778
+69
| +0.7% | +$5.31K | 0.01% | 1249 |
|
|
2020
Q2 | $757K | Sell |
9,709
-28,313
| -74% | -$1.92M | 0.01% | 1315 |
|
|
2020
Q1 | $2.22M | Sell |
38,022
-4,143
| -10% | -$267K | 0.02% | 746 |
|
|
2019
Q4 | $3.38M | Buy |
+42,165
| New | +$3.16M | 0.03% | 810 |
|
|
2018
Q4 | – | Sell |
-47,412
| Closed | -$3.7M | – | 2183 |
|
|
2018
Q3 | $3.7M | Buy |
47,412
+1,150
| +2% | +$79.9K | 0.02% | 893 |
|
|
2018
Q2 | $2.94M | Buy |
46,262
+5,911
| +15% | +$470K | 0.02% | 1026 |
|
|
2018
Q1 | $3.7M | Buy |
40,351
+4,005
| +11% | +$345K | 0.01% | 1189 |
|
|
2017
Q4 | $2.74M | Buy |
+36,346
| New | +$2.56M | 0.01% | 1437 |
|
Other funds holding BPMC
IA
HNB
Guggenheim Capital's BPMC Position: Q3 2025 in Review
Guggenheim Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 14,624 shares — an estimated $1.87M sold.
Guggenheim Capital first reported a position in BPMC in Q4 2017 and held it in 27 quarters. The position peaked at $4.76M in Q3 2021. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Guggenheim Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Guggenheim Capital sold 14,624 Blueprint Medicines shares in Q3 2025, an estimated $1.87M.
- Guggenheim Capital first reported a position in Blueprint Medicines in Q4 2017 and held it in 27 quarters.
- Guggenheim Capital's Blueprint Medicines position peaked at $4.76M in Q3 2021.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Guggenheim Capital's 13F filing for Q3 2025, filed 13 Nov 2025.